Morepen Laboratories Board Meeting Outcome

Morepen Laboratories Product Launch

Morepen launched Desloratadine Tablets USP 5 mg, its first US prescription generic, through subsidiary Morepen Bio Inc. It also filed a Sitagliptin ANDA with the US FDA.

Morepen Laboratories Management Change

Morepen Laboratories announced promotions effective 27 October 2026 for two senior management personnel. Charanjeet Chitakara moves to Assistant Vice President (Quality Control) and Vivan Prashar to Vice President (Projects & Engineering).

Morepen Laboratories Other Announcement

Morepen filed its Q2FY27 Monitoring Agency Report confirming Nil deviation in QIP proceeds utilization. The company spent ₹1.12 crore on modernization and expansion during the quarter.

Morepen Laboratories Investor Presentation: Key Takeaways

Q2 FY27 revenue Rs755 Cr (+81%), PAT Rs89 Cr (+117%), EBITDA margin 17.45% (+897bps). H1 revenue Rs1,330 Cr (+57%). CDMO scale-up drives mix.

Morepen Laboratories Results Update

Morepen hit record Q2 FY27 revenue up 81% and EBITDA up 273%, driven by CDMO scale-up. H1 EBITDA reached ₹220 Cr; API+CDMO capacity now 614 KL.

API + CDMO manufacturing capacity

614 KL

Morepen Laboratories Q2 FY27 Results: Net Profit ₹88.9 Cr, Up 117.4% YoY

Morepen Laboratories Ltd reported revenue from operations of ₹746.5 Cr (+81.4% YoY) and net profit of ₹88.9 Cr (+117.4% YoY) for Q2 FY27.

Key figure

Net profit ₹88.9 Cr · +117.4% YoY

Ennature Bio Pharma Board Meeting Outcome

Ennature Bio Pharma's board approved adoption of new Articles of Association to align with SCRA Rules 1957 and group governance. The change is subject to shareholder approval.

Shri Keshav Cements & Infra Board Meeting Outcome

Shri Keshav Cements' board approved un-audited financial and segment-wise revenue results for the quarter and half-year ended 30 September 2026. No other material decisions were transacted.

Balmer Lawrie Investments Board Meeting Outcome

Balmer Lawrie Investments appointed M/s. K. K. Chanani & Associates as Statutory Auditor for FY 2026-27 under Section 139(5), per a C&AG letter. The appointment is effective from 10 November 2026.

Execution

FY 2026-27

Jiwanram Sheoduttrai Industries Board Meeting Outcome

Jiwanram Sheoduttrai's board approved convening its 29th AGM on 30 November 2026 and re-appointing a retiring non-executive director. The board also approved the FY2025-26 Board's Report.

Finolex Cables Board Meeting Outcome

Finolex Cables' board approved amending its insider trading code of conduct on 7 November 2026. Amended code was filed under PIT Regulation 8(2).

Chatterbox Technologies Board Meeting Outcome

Chatterbox's board approved a Rs. 7 crore related-party ceiling with its UAE subsidiary and a vendor change for IPO funds. Monitoring agency and deviation reports were also noted.